Chugai Seiyaku Kabushiki Kaisha

Kiyoshi Habu

Hideki Adachi

Naohiro Yabuta

Kou-ichi Jishage

Masayuki Tsuchiya

Hiroyuki Tsunoda

Yuichi Hirata

Izumi Sugo

Yasuo Sekimori

Shigeyuki Iijima

Kenju Ueno

Kou-Ichi Jishage

Promoter activities were examined by comparing combinations of promoters and enhancers derived from various genes. A hybrid promoter comprising a combination of a CMV enhancer and a mammalian &#x3b2;-actin promoter, or the post-transcriptional regulatory region of the genomic sequence Woodchuck Hepatitis Virus (WPRE) and a mammalian &#x3b2;-actin promoter was found to be stronger than existing promoters. Furthermore, the activities of the &#x3b2;-actin promoters could be enhanced by coexpressing the oncogene product Ras, which is a transactivator.

Expression systems using mammalian beta-actin promoter

A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.

Methods of using human tissue factor-producing knock-in mice

The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited. The present invention further relates to a method for producing recombinant protein, and specifically, to a method for producing protein by which fucose existing within the Golgi apparatus of a host cell is decreased, a method for inhibiting the addition of fucose to protein by which fucose existing within the Golgi apparatus of a host cell is decreased upon production of recombinant protein using the host cell, a method for increasing the cytotoxic activity of an antibody by which an antibody is produced using a cell wherein fucose existing within the Golgi apparatus is decreased, and a cell having a Golgi apparatus wherein fucose existing within the Golgi apparatus is decreased.

Fucose transporter

A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.

SGRF gene-modified mouse

Knock-in non-human animal producing human tissue factor

Growing community of inventors

Ibaraki, Japan

Kiyoshi Habu